Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Azemiglitazone
Cat. No.:
0225LY-0616
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
Azemiglitazone is an insulin-sensitizing compound being researched for the potential treatment of diabetes.
Synonym:
1133819-87-0; 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione; 2,4-Thiazolidinedione, 5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-; 5-{4-[2-(3-methoxyphenyl)-2-oxoethoxy]benzyl}-1,3-thiazolidine-2,4-dione; 5-({4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione; 5-[4-[2-(3-Methoxyphenyl)-2-oxoethoxy]benzyl]-1,3-thiazolidine-2,4-dione
CAS No.:
1133819-87-0
Compound CID:
25230266
Formula:
C19H17NO5S
Formula Weight:
371.41
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Azemiglitazone can be used in metabolic disease research to study its role as a PPAR gamma agonist in insulin sensitivity.
Library Information
Target:
mTOR
Receptor:
mTOR
Pathways:
PI3K/Akt/mTOR signaling; Metabolism
Plate Number:
AOCL-8
Plate Location:
h11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
125 mg/mL; 336.56 mM
Water Max Solubility:
<0.1 mg/mL (insoluble)
